Documentos de Perera Y. | REDI

Regresar

Mostrando 3 resultados de: 3

Filtros aplicados

Origen: "scopus"

Subtipo de publicación

Publisher

British Journal of Cancer(1)

Journal of Pharmaceutical and Biomedical Analysis(1)

Molecular and Cellular Biochemistry(1)

Área temáticas

Enfermedades(2)

Farmacología y terapéutica(2)

Ginecología, obstetricia, pediatría, geriatría(1)

Área de conocimiento

Espectrometría de masas(1)

Año de Publicación

Origen

Palabras Claves

Anti-tumor peptide(1)

B23/nucleophosmin(1)

Bio-analytical method(1)

Cancer targeted therapy(1)

Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasma

Abstract: A fully validated bio-analytical method based on Matrix-Assisted-Laser-Desorption/Ionization-Time of

Palabras claves:

Anti-tumor peptide, Bio-analytical method, Full validation, Human plasma, Maldi-tof

Audain E., B. G. De la Torre, Besada-Pérez V., Cabrales-Rico A., Garay H.E., Gómez J.A., González L.J., Machado Y.J., Marcelo J.L., Morales O., Perea-Rodríguez S.E., Perera Y., Reyes O., Reyes V.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo

Abstract: Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, w

Palabras claves:

apoptosis, Cancer targeted therapy, Casein kinase 2

Acevedo B.E., Alonso D.F., Ariosa J., Bacardí D.M., Baladron I., Besada-Pérez V., Betancourt L., Castellanos L.R., Cosme K., Cruz M., Díaz A., Falcón-Cama V., Farina H., Garay H.E., Gil J., Gómez D., Gómez R., González L.J., Hernández I., Herrera L., López C., López-Mola E., López-Saura P.A., Marcelo J.L., Mendoza O., Perea-Rodríguez S.E., Perera Y., Puchades Y., Reyes O., Rodriguez A., Sánchez A., Santana A., Serrano J.M., Sigman H., Silva R., Solares M., Thelvia I. Ramos Gómez, Valenzuela-Silva C.M.

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

Abstract: Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecti

Palabras claves:

B23/nucleophosmin, Cervical Cancer, CIGB-300, tumour uptake

Acevedo B.E., Alonso D.F., Ancízar J.A., Baladron I., Casacó C.A., Coca M.A., García I., Gómez R., González L.J., González Y.M., Hernández I., I. Howland-Álvarez, López-Saura P.A., Martínez Y.M., Molina L., Perea-Rodríguez S.E., Perera A., Perera Y., Prats A., Reyes V., Solares M., Torres L.A., Valenzuela-Silva C.M.